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Colicins are bacterial toxins that kill Escherichia coli and related cells; their mode of action is of
interest in protein import and toxicology. Colicins translocate across the E. coli outer membrane and
periplasm by interacting with several receptors. This translocation process involves interaction of the
colicin with the outer membrane porin OmpF and subsequently with the integral membrane protein
TolA. The N-terminal domain of colicin N is involved in the import process. Our aim was to produce a
large quantity of colicin A for functional and structural studies. It is a prerequisite to have a correctly
folded and stable protein for these studies. The commonly utilised expression system uses the Lex A
promoter, which requires induction with toxic mitomycin C, though the yield is low. Here we present
the production of an E. coli toxin and its immunity protein in E. coli using a safe inducible promoter.
Key Words: Protein production, Toxin, colicins, Immunity protein.

Introduction
The ultimate aim of biochemistry is to decipher how events occur inside of living cells or organisms. The living
cell must also be regarded as the ideal model system for any biochemical application, as most physiological
targets are found inside living cells. The cell envelope of the Gram-negative bacterium Escherichia coli
is a complex structure and many of the proteins found in the bacterial envelope are involved in import
mechanisms. A variety of bacterial toxins have taken advantage of some of these envelope proteins to enter
the bacteria. Pore-forming toxins present the important challenge of the translocation process, and the study
of the membrane insertion mechanism of pore-forming colicins has also become a very important subject.
How these proteins pass through or integrate into membranes is still one of the fundamental unsolved
problems in biochemistry.
Colicins are plasmid-encoded toxin proteins produced by immune E. coli that are active against
sensitive E. coli and closely related cells. Their toxic activities are of various types; some colicins form ion
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channels in the cytoplasmic membrane of sensitive cells, while others act as nucleases that degrade DNA or
16s RNA in the cytoplasm, and one, colicin M, inhibits the biosynthesis of murein1 . Their toxic activities
against target cells are known to occur in three distinct stages. The first step is receptor recognition and
binding, where colicins bind to a specific receptor at the cell surface2 . This is followed by the translocation
step, where colicins cross both the outer membrane and periplasm to reach their cellular target 1−2 . The
final stage is the killing action, where colicins exert their lethal effects either by 1. Formation of a pore in
the cytoplasmic membrane3 , 2. DNAse or RNAse activity or 3. Inhibition of murein biosynthesis in the
cytoplasm (for review see reference 1).
Colicins have three linearly organised functional domains, each domain being implicated in a specific
stage of colicin activity. The central domain (R-domain) is responsible for the receptor-binding activity. The
N-terminal domain (T-domain) is involved in translocation. The C-terminal domain (P-domain) carries the
lethal activity, and this domain either forms a voltage gated pore in the cytoplasmic membrane or digests
nucleic acids in the cytoplasm4−6.

T

R

P

Figure 1. The domain structure of colicins. These domains (T, R and P) deviate from the domain sizes of colicin N
determined by El-Kouhen7 . The N-terminal domain is involved in the translocation step and is called the T domain.
The central domain of colicin N is termed the R domain and it contains information required to bind to the receptor.
The C-terminal section is required for the lethal activity of pore formation and it is called the P domain.

Colicin A and colicin N are members of a group A (Tol dependent) pore-forming colicin whose target
receptor is the E. coli outer membrane protein OmpF8 . Colicin translocation requires three members of the
Tol locus: Tol A, Tol Q and Tol R10. Tol Q and Tol R are integral membrane proteins of the E. coli inner
membrane and there is no evidence that they reach across the periplasm to the outer membrane. However,
Tol A is thought to span the periplasm by means of its extended central domain (Tol A-II), which links
the N-terminal Tol A-1 domain in the cytoplasmic membrane to the C-terminal Tol A-III domain11. The
interaction between Tol A-III and the N-terminal domain of colicins is thought to be the principle event
of translocation12 . All the translocation domains of colicins interact with periplasmic receptors and can
be divided into two groups: those that bind to the Tol proteins and those that bind to the Ton proteins.
This division was identified early in the history of colicin research and the Tol proteins were named because
mutations on Tol proteins render cells “tolerant to colicin”. This is still, along with resistance to filamentous
phage, the clearest phenotype of Tol protein mutants10 . The Ton proteins such as Ton B, on the other hand,
have a clear role in active transport across the outer membrane23 . The tol system consists of the proteins
Tol A, B, Q and R. Tol A is analogous to Ton B in that it consists of a cytoplasmic transmembrane domain
(domain I) joined to a C-terminal, possibly outer membrane domain (domain III) by an extended region
of repetitive secondary structure (domain II)24 . In the case of Tol A, this linker region is proposed to be
α-helical, but it may fold back upon itself several times rather than being a straight rod-like structure. If
the structure were straight this 230 amino acid residue section would be much longer than the width of the
periplasm25 . Group A colicins are known to bind to Tol A-III via their N-terminal translocation domains.
In the case of colicin A, the area of interaction has been defined using deletion mutants26 . For colicin N
, site-directed mutagenesis and biophysical measurements such as calorimetry and fluorescence were used
on the isolated N-terminal domain to define a series of residues required for Tol A binding9 . Colicin N
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is composed of a largely unstructured T- domain linked by a glycine-rich sequence to a central R-domain
containing a six-stranded β-sheet structure. The R-domain is connected to the P-domain (a 10 α-helical
structure) by means of a 65Å α-helix7−9 . While receptor binding and pore formation have been extensively
studied, much remains unknown about the translocation step.
The main defence against pore-forming colicins for E. coli strains are the colicin immunity proteins
encoded by the immunity gene. Immunity proteins for pore-forming colicins are integral cytoplasmic
membrane proteins with three or four predicted transmembrane helices and are highly specific for a particular
colicin. It is predicted that the inactivation of pore-forming colicin by their immunity proteins occurs in
the membrane just prior to channel opening18 . It has been shown that the immunity protein of colicin A
interacts with the pore forming domain in the inner membrane8 . The immunity protein thus does not appear
to stop the colicin from binding and translocating across the outer membrane, but prevents it from forming
a pore once it is inserted into the cytoplasmic membrane 23 .
The production and purification of recombinant proteins is an important step in the biochemical
analysis and functional characterisation of proteins. A widely used strategy for protein isolation involves
expression of the protein in bacterial cells. The production of E. coli toxins in E. coli often leads to low-level
production and extensive proteolysis that limit the application of this approach to stable toxin proteins.
The natural expression system of colicin A must be induced by mitomycin C, which is a potent carcinogen.
In the course of our attempts to express this colicin without using mitomycin C induction, we encountered
significant difficulties, especially low-expression yield and proteolysis of colicin in E. coli.
To solve these problems, a high-level expression system was constructed and the overproduction of
colicin A in E. coli is presented in this paper. This system additionally contains an immunity protein gene
against colicin A and allows for the production of both colicin A and an immunity protein against it.

Experimental
Bacterial Strains and Plasmids
Construction of pISACOLA was completed in two steps. First, DNA encoding the colicin A and immunity
protein was amplified using two oligonucleotides with 18bp matching sequence to colicin A and immunity
proteins.
1. ColAXhoI-Sense: TTTTTCTCGAGCATGCCTGGATTTAATTATGG
2. ImmAMluI-reverse: TTTTTTTTACGCGTCTCCGGTAACGATAGATG
Plasmid pCA31 carrying wild-type colicin A and immunity protein was used as a template 27 . Second,
the PCR product (DNA fragment encoding colicin A and immunity protein) was gel purified and ligated
into purified, digested vector plasmid pET8C

28

using Xho I and Mlu I restriction sites. The pET8C vector

introduces a methionine, six histidines and two serine (NH2-MHHHHHHSS-) linkers at the N-terminus of
any gene inserted between Xho I and Mlu I restriction sites
purification by nickel affinity chromatography

13

28

. This 6 His and 2 Ser linker facilitates

. The resulting histidine-tagged colicin A protein is under

the control of a T7 promotor on the vector. This final construct (pISACOLA) was used initially to transform
E. coli DH5α cells with ampicillin selection. Successful transformants were selected on the basis of ampicillin
resistance, mini-prep restriction digest analysis or analytical PCR, and a subsequent plasmid preparation
was used for DNA sequencing or to transform E. coli BL21 (DE3) cells. DNA sequencing of this plasmid
showed that both colicin A and immunity protein were correctly inserted. A circular plasmid map of this
325
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construct is shown in Figure 2.

Protein Purification
E. coli BL21(DE3) cells were transformed with pISACOLA and grown in 3 ml O/N cultures of LB medium
containing ampicillin (200 µg/ml). A 3 ml O/N culture was introduced into 500 ml of LB containing
ampicillin (200 µg/ml) and grown at 37 ◦C. The cells were induced at OD600 0.8-0.9 with isopropyl β-Dthiogalactopyranoside (1 mM IPTG), and grown for a further 3 h. The cells were harvested and resuspended
in 20 mM phosphate, 300 mM NaCl, pH 7.4, buffer containing RNAse (20 µg/ml) and DNAse (20 µg/ml).
The cells were lysed by French press and the supernatant was obtained by centrifugation at 40,000 rpm
(125,800 x g) in a Beckman ultra-centrifuge with a 45Ti rotor for 1 h at 4 ◦C. The fusion protein was found
to be soluble, with none remaining in the cell membrane pellet. The N-terminal 6 X Histidine-tag facilitated
purification of the fusion by means of a Qiagen Ni-NTA (nickel nitrilotriacetic acid) affinity column14 . The
toxin protein was washed onto the column with 50 mM phosphate, 300 mM NaCl, pH 8.0 buffer, additionally
washed with the same buffer containing 30 mM imidazole, and eluted in 300 mM imidazole, pH 7.0 using 5
ml of buffer for each fraction. The toxin was analysed for purity by 12% SDS-PAGE (Figure 3). A sample
of was taken from each fraction and after the addition of 5 µl of sample buffer, the 10 µl protein samples
loaded on to the 12% SDS-PAGE gel. SDS-PAGE was carried out as described by Laemmli20; the reservoir
buffer was 0.125 M Tris, 0.96 M Glycine and 0.5% SDS pH 8.3 and the sample buffer was 0.25 M Tris,
8% SDS, 0.02% Bromphenol blue and 40% Glycerol pH 6.8. Electrophoresis was carried out at a constant
current of 24 mA After electrophoresis, proteins in the gel were visualised by staining with 0.20% Coomassie
Brilliant Blue in a solution of 30% isopropanol and 10% acetic acid and then destained overnight in aqueous
acetic acid/isopropanol (10% acetic acid, 10% isopropanol). The protein concentration of purified colicin A
toxin was determined from ultraviolet absorption at 280 nm, using the extinction coefficient for A280 : 51,350
M−1 cm−1 , calculated from the number of tryptophan and tyrosine residues in the sequence. The validity of
calculated A280 as an accurate measure of protein concentration has been verified previously

19

.

Circular Dichroism (CD) Spectroscopy
Far-UV-CD spectroscopy was carried out on a Jobin-Yvon CD6 spectra polarimeter. Measurements were
performed at 20 ◦ C using a 0.2 cm path length cuvette (Hellma), and protein concentration of 0.5 mg/ml.
The protein was in 50 mM phosphate, 300 mM NaCl, pH 7.4, buffer, and this was also used for baseline
subtraction. The CD signal measured was mean residue ∆ε (M−1 cm−1 ).

Colicin Toxicity
An in vivo cell survival assay using fluorescent probes has been previously described31 . E. coli BE3000 cells
were grown in LB medium to an OD600 of 0.5 (5 × 108 cells/ml), washed in water and reconstituted in 10
mM phosphate, pH 7.4, to a concentration of 5 × 109 cells/ml, and stored on ice. Measurements of toxicity
were determined by the fluorescence colicin depolarisation of E. coli cells29−30 followed by a change in ANS
fluorescence using an SLM 8100 spectrofluorometer operating in ratio mode with spectral band-widths of 8
nm for both excitation and emission, excitation wavelength was 360 nm and emission was measured between
400 and 550 nm. For measurement, 0.3 ml of cells was mixed with 2.7 ml of phosphate buffer, and 150 µl
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of ANS (8-anilino-1-napthalenesulphonic acid) was added after 100 s (1 µM) and left to equilibrate. Five
microlitres of colicin A, 10 µg/ml was added after 300 s. The fluorescence increase was monitored for 2000
s.

Results and Discussion
Details on the construction of pISACOLA plasmid are given in Figure 2 and the experimental section.
The pET8c vector was used to clone the genes encoding colicin A and immunity protein of colicin A. This
vector is under the tight control of the T7 promoter that facilitates the expression of toxic proteins13−15,16.
Our construct also includes an N-terminal poly-histidine tag (6 histidines) for simple and efficient protein
purification. DNA sequencing of this constructed plasmid (Figure 2) confirmed that the desired inserts were
successfully cloned into a pET8C expression vector and also that the constructs were in the correct reading
frame.
Xho I

NH2-HHHHHHSSN-terminal-His-tag

T 7
Colicin

A
m
p
pIsaColicin
O

stop

r
i
l

a c

Immunity protein

Mlu I

Figure 2. Circular plasmid map of the pISAColA constructed to produce colicin A and its immunity protein. Xho I
and Mlu I restriction enzymes were used and their sites are shown. Amp: ampicillin resistance gene and T7: promoter
from T7 phage, Ori: origin of replication, lac: lac operon.

The fusion protein was purified from the E. coli cell lysate as described in the experimental section.
Ni-NTA agarose resin was used to purify the fusion protein from the supernatant of E. coli cell lysate
after ultra-centrifugation. Proteins containing the histidine affinity tag bind to Ni-NTA agarose resin with a
greater affinity than other E. coli proteins. Non-specifically bound proteins were washed through the column
without affecting the binding of His-tagged fusion protein. Elution of the fusion protein from the column
was achieved by imidazole, which competes with the His tag for interaction with the Ni-NTA resin.
Eluted samples were analysed on SDS-PAGE and showed a strong protein band with a molecular
mass of around 63 kDa. The calculated molecular weight of the fusion protein using ProtParam tool (Swiss
Institute of Bioinformatics) was 62,992 Da which is very close to the experimental molecular mass, extinction
coefficient of this fusion at 280 nm is 51,350 M−1 cm−1 and its theoretical pI is 7.78 (these data were calculated
using ProtParam tool, its web address is http://expasy.proteome.org.au/cgi-bin/protparam). The protein
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yields were calculated using UV absorbance at 280 nm. One litre of BL21 (DE3) E. coli cell culture gave
more than 30 mg (35-40 mg) of highly pure toxin protein.
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Figure 3. Colicin A expression in E. coli BL21 (DE3) cells. 1: Supernatant after ultra-centrifugation (before NiNTA resin). 2: Flow through from the Ni-NTA resin. 3: Elution fraction 1 in 300 mM imidazole, 50 mM phosphate
and 300 mM NaCl. 4: Molecular weight markers (66 kDa, 45 kDa, 36 kDa, 29 kDa, 24 kDa, 20.1 kDa). 5: Elution
fraction 2. 6: Elution fraction 3. 7: Elution fraction 4. 8: Elution fraction 5.

The event central to the translocation process is the interaction of colicin T-domain with Tol A-III.
Studies of colicin A have shown that translocation is accelerated in urea, indicating that colicins are likely
to unfold to expose the T-domain allowing interaction with Tol A2 . The structure of the T-domain of any
colicin before and after interaction with Tol A is still unknown. Despite obtaining crystals of residues 36-397
of colicin N6 , the final solved structure lacked the N-terminal 90 residues and gave no structural information
on the N-terminal domain structure of colicin N (residues 1-66). The only member of the colicin family whose
full-length structure is known is colicin Ia17 . While its pore-forming domain adopts a similar 10 α−helical
fold to colicin N, its N-terminal domain appears largely unstructured.
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Figure 4. Circular dichroism spectrum of colicin A produced by the T7 promoter system described in the text.
Colicin A in at a concentration of 0.5 mg/ml phosphate buffer was placed in a 0.2 mm pathlength cuvette. The
spectra were collected at 20 ◦ C in a Jobin-Yvon CD6 spectra polarimeter.

The strategy of the high level production of colicin A is based on the production of two different
proteins together in E. coli. It is already known that one of them is the colicin A toxin protein and the
other one is an immunity protein against the same toxin. The activity of the immunity proteins of the
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channel-forming colicins is poorly understood. The channel domain of colicin A is inhibited by its immunity
protein through direct interaction in the E. coli inner membrane but the ability of a single channel-forming
colicin to kill a cell is prevented only by the immunity protein that is coded by the same plasmid18. The
protective mechanism of the immunity protein is a unique aspect of the interaction of colicins with cell
membranes and immunity protein toxin interaction. Immunity proteins recognise their target colicin most
probably through direct interaction and inhibit its killing activity, or they may also interact with the inner
membrane components of the translocation machinery to prevent the insertion of colicin A into the inner
membrane1 .
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Fluorescence
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Figure 5. Effect of the addition of full length histidine tagged colicin A and wild-type colicin A on the change in
fluorescence of potential sensitive probe ANS. The fluorescence, measured at 480 nm, of the sensitive BE300 cells was
allowed to stabilise. ANS added at the first arrow and caused a jump in fluorescence. Both wild-type and histidine
tagged recombinant (His-Tagged) colicin A toxin were added at the second arrow at a ratio of 400 colicins per cell.
After translocation the colicin A toxin causes membrane depolarisation by channel formation in the inner membrane
of E. coli.

As mentioned earlier, the gene construct consists of two proteins originating from different parent
molecules. The plasmid we describe here (pISACOLA) permits the production of colicin A under the tight
control of the T7 promoter system. It was prepared to allow constitutive expression of the col A immunity
protein and thus obtain a high level of the inducible expression of colicin A. The addition of the histidine tag
(6 His) was used for the purification of this fusion protein by a single affinity chromatography step, but it also
reduces proteolysis of the flexible N terminal region of this protein. The pET8c construct gives high yields of
stable protein and it is a critical step for the crystal structure studies. Structural and biophysical knowledge
of this protein will aid our understanding of colicin translocation through the cell envelope of Gram-negative
bacteria. The secondary structure of colicin A was determined by circular dichroism spectroscopy. The
results (circular dichroism spectrum of recombinant colicin A gave the ratio of 38% helix, 26% beta and
other 36%) indicate the toxin to be a fully folded α helix rich protein in agreement with measurements
previously published for the wild-type protein21 . The toxicity tests show that there was no difference
between wild-type colicin A and our recombinant colicin A toxin. The toxicity of full length histidine tagged
colicin A was confirmed using the potential sensitive fluorescent probe ANS29 . After receptor binding and
translocation the colicin causes membrane, depolarisation by channel formation in the inner membrane as
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shown in Figure 5. This behaviour of His-tagged colicin A is identical to that native non His-tagged colicin
A toxin30 .
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